Due to the significant efficacy shown in the phase I clinical trial, ceritinib was approved by FDA in 2014 for the treatment of patients with ALK-positive metastatic NSCLC that progressed or could not be tolerated after crizotinib treatment. Here, ALK is linked to non-small cell lung carcinoma.